This product is a formyl derivative of tetrahydrofolate, mainly used for the rescue of high-dose methotrexate and other folic acid antagonists. It is converted into tetrahydrofolate by tetrahydrofolate reductase, which can effectively counteract the toxic reaction caused by methotrexate, limit the degree of damage to normal cells by methotrexate, and reverse the reaction of methotrexate to bone marrow and gastrointestinal mucosa, but has no obvious effect on the existing methotrexate neurotoxicity.

Extract from the above information

Febuxostat is a 2-arylthiazole derivative and a xanthine oxidase inhibitor that reduces serum uric acid concentration by inhibiting uric acid synthesis. Febuxostat does not inhibit other enzymes involved in the synthesis and metabolism of purines and pyrimidines at conventional therapeutic concentrations.

Extract from the above information

Gatifloxacin is a racemic compound of 8-methoxyfluoroquinolone, which has a broad spectrum of activity against Gram-negative and Gram-positive microorganisms in vitro. Its R- and S-enantiomers have the same antibacterial activity. The antibacterial effect of this product is through inhibiting bacterial DNA gyrase and topoisomerase IV, thereby inhibiting bacterial DNA replication, transcription and repair processes. It has antibacterial activity against most strains of the following microorganisms: 1 Gram-positive bacteria: Staphylococcus aureus (limited to strains sensitive to methicillin), Streptococcus pneumoniae (strains sensitive to penicillin). 2 Gram-negative bacteria: Escherichia coli, Haemophilus influenzae and parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Neisseria gonorrhoeae, Proteus mirabilis. 3 Other microorganisms: Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae.